AB Science Completes EUR 2.3 Million Private Placement
Biotechnology company AB Science announced the successful completion of a capital increase, raising EUR 2.3 million in gross proceeds from a limited number of investors on July 1, 2026. The use of funds has not been detailed.
Biotechnology firm AB Science announced on July 1, 2026, the successful conclusion of a private placement that generated EUR 2.3 million in gross proceeds. The capital increase was subscribed by a limited number of investors.
The company has not specified the intended use for the funds raised. AB Science's operations typically focus on drug development and clinical research, particularly its investigations into masitinib and AB8939 for various medical conditions.
AB Science has previously reported on its clinical studies evaluating masitinib for neurodegenerative and inflammatory diseases, including multiple sclerosis and Alzheimer's disease, as well as its research into AB8939 for oncology applications.
Recent company announcements have also covered board restructuring and progress in Phase 1 clinical trials for AB8939. The private placement is likely intended to support these ongoing research and development initiatives, consistent with the company's business model.